Share Twitter LinkedIn Facebook Email Rod A. Humerickhouse, MD, PhD, Group Project Leader, Oncology Development, AbbVie, discusses Testing For Minimal Residual Disease In CLL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com
Positive Outcomes & Tolerability Sonrotoclax + Zanubrutinib in TN-CLL/SLL – ASH 2023 Updates Chronic Lymphocytic Leukemia 1 Min Read
BTK Inhibitor Use and Social Determinants in CLL / SLL [ASH 2023] Chronic Lymphocytic Leukemia 2 Mins Read
Elevate-TN: Treatment-Naive CLL Treated with Acalabrutinib – ASH Chronic Lymphocytic Leukemia 2 Mins Read